Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized adaptive trial of COMIRNATY booster after VAXZEVRIA
2021-001978-37Phase 2Active
- Sponsor
- Instituto de Salud Carlos III
- Start
- May 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of tozinameran in coronavirus disease 2019 (COVID-19), sponsored by Instituto de Salud Carlos III. Primary endpoint: Primary humoral immune response at Day 14. Started May 2021; status: active.
02
Drugs
tozinameran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2021-001978-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001978-37.